Adipolin and IL-6 Serum Levels in Chronic Obstructive Pulmonary Disease

Adv Respir Med. 2022 Sep 7;90(5):391-398. doi: 10.3390/arm90050049.


Objective(s): One of the adipokines that have insulin-sensitizing properties is adipolin, whose reduced levels have been reported in obesity, oxidative stress, and inflammation. The present study investigated serum interleukin-6 (IL-6) and adipolin levels in chronic obstructive pulmonary disease (COPD) patients. Method: A control case study included 60 COPD patients and 30 healthy subjects in the research and measured adipolin and IL-6 serum levels. In addition, serum adipolin levels in COPD patients were assessed according to the GOLD grade. The relationship between serum adipolin levels and study variables were also analyzed. Results: The results showed reduced adipolin levels in COPD patients compared with healthy individuals (p < 0.001). Furthermore, increased levels of IL-6 were evident in the COPD group compared to the control group (p < 0.001). Adipolin serum levels were positively correlated with PFTs and negatively correlated with IL-6 levels. Conclusion: Decreased adipolin levels enhanced disease severity in COPD patients. It seems that the existence of a significant relationship between adipolin and IL-6 may indicate the role of adipolin in the pathophysiology of COPD.

Keywords: COPD; IL-6; adipolin.

MeSH terms

  • Adipokines
  • Humans
  • Insulins*
  • Interleukin-6
  • Obesity
  • Pulmonary Disease, Chronic Obstructive*


  • Adipokines
  • C1QTNF12 protein, human
  • IL6 protein, human
  • Insulins
  • Interleukin-6

Grants and funding

The current study was funded by Ardabil University of Medical sciences, Ardabil, Iran.